SEMA4D and metabolic dysfunction-associated steatohepatitis: An anti-α8 neutralizing mAb was evaluated in three different murine fibrosis models: for cytotoxic (CCl<sub>4</sub> treatment), non-alcoholic steatohepatitis-associated and cholestatic fibrosis.